VELEX, a novel device for the treatment of CVI. Credit: I-VASC / Business Wire.

Italian medical device firm I-VASC has raised $1.95m (€1.8m) in a Series A financing round to launch VELEX, a device to treat chronic venous insufficiency (CVI).

The Luca Trevisan, Bootes (Rosario Bifulco), Nalini family Office and other qualified investors participated in the financing round along with former shareholders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company intends to use the funding for post-market clinical studies of the VELEX device, to complete the industrialisation of the product and to obtain approval for the US market from the Food and Drug Administration (FDA).

VELEX is a patented minimally invasive medical device that is developed for the empty vein ablation (EVA) procedure in CVI patients.

Claimed to be the company’s first CE Marked device, the non-thermal, non-tumescent endovascular device comprises a percutaneous three-ballon catheter that allows the performance of chemical ablation (Schlerotherapy) following isolation and removal of blood from the vein portion that needs to be treated.

See Also:

I-VASC stated that this process enables full control of the schlerosant agent contact, distribution and time.

The newly appointed I-VASC CEO Daniele Zanotti said: “I am thrilled to embrace this new professional adventure and put my experience at the service of a project which has the potential of representing a new paradigm in the largely underserved market of CVI and varicose vein.

“With the considerable efficacy, safety and usability improvements that VELEX can offer with respect to all alternative methods, we have the opportunity to offer a better option to millions of patients and create a huge new value in the vascular arena.”

I-VASC raised $81,571 (€75,000) in the first half of last year, as well as another $1.159m (€1.066m) before the end of the year.